Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertain

Jazz Pharmaceuticals Faces Setback in Essential Tremor Drug Trial

Jazz Pharmaceuticals faced a significant hurdle on Thursday when its phase 2b trial for an essential tremor drug failed to meet its primary endpoint. Despite this obstacle, the company noted some numeric improvements and is awaiting additional data from another study before making any final decisions about the program.